| Background and Objective: Urotensin-II(U-II), a cyclic undecapeptide with an intramolecular ring structure connected by two cysteine esidues, originally isolated from the caudal neurosecretory system of the fish has been identified as a vasoactive peptide in mammals. We observed UII expression in the cardiovascular tissue and nerve tissue widely. Currently, UrotensinⅡis the strongest vasoconstrictor peptide in vivo, and may correlate with atherosclerosis closely. Metabolic syndrome is one group of clinical syndromes seriously affecting human health: central obesity, diabetes or impaired glucose regulation, hypertension, dyslipidemia as the main content, insulin resistance as the common pathophysiological basis, variety of metabolic disorders as the clinical features. Metabolic syndrome is currently considered as a high-risk factor of cardiovascular and cerebrovascular events. Studies have shown that it is not very chear that the mechanisms of UⅡin the occurrence and development of metabolic syndrome and the relationship between UⅡand the macrovascular disease in patients with metabolic syndrome . In this study, by observing the level of UⅡ, ET-1 and NO in healthy persons and patients with metabolic syndrome, we make resarch of the relationship between UⅡand endothelial function.Methods: According to the 2005 IDF criteria for the diagnosis of metabolic syndrome, chosed 100 patients without hematological system disease, hepatic and kidney disease, gout, cancer and thyroid diseases and so on ,including 55 men and 45 women with the age range from 41～72(56.63±12.33). At the same time, chosed 31 healthy persons as the control group, including 15 men and 16 women with the age range from 35～68(54.46±12.75). The blood pressure, body mass index, smoking history and family history of all subjects were collected . Measured blood glucose, blood fat, hepatic and renal function with venous blood drawed on an empty stomach. Measured the plasma UⅡby enzyme-linked immunosorbent assay method, measure the endothelin-1(ET-1) by radioimmunity method, and measure the NO by nitrate reduction colorimetric method.Used SPSS10.0 for statistical analysis. Describe measurement data by x±S, and compared mean of two groups by t-test or F-test. Measure the relevance between UⅡand endothelial function indicator by Pearson correlation analysis.α=0.05 P < 0.05 is significant statistical difference.Results: (1) Bwtween the two groups, the age,sex ratio,height,weight,Cr,LDL-C all have no significantly difference (P>0.05), and the abdomen circumference,BMI,SBP,TG,HDL-C all have significantly difference (P<0.05). ( 2 )Compared the level of UⅡ,ET-1,NO between the two groups by t-tset, the result is: the plasma urotensinⅡlevels in the patients with metabolic syndrome was significantly higher than control group(0.321±0.107 ng/ml vs 0.499±0.205 ng/ml,P<0.001); the plasma ET-1 levels in the patients with metabolic syndrome was significantly higher than control group(57.156±10.205 vs 74.201±13.382,P<0.001); the plasma NO levels in the patients with metabolic syndrome was significantly lower than control group(92.150±35.017 vs 50.278±23.519,P<0.001). (3)By doing Pearson correlation analysis to analyze the correlation of UⅡwith ET-1 and NO, we can see that UⅡhas positive correlation with ET-1, the coefficient of correlation is 0.5402. And UⅡhas negative correlation with NO, the coefficient is -0.4558. Both of them have statistical significance (p<0.05).Conclusion: (1)The plasma urotensinⅡlevels in patients with metabolic syndrome is higher than healthy persons, suggesting that the plasma urotensinⅡmay be concerned with certain metabolism of metabolic syndrome; (2) In patients with metabolic syndrome, UⅡhas positive correlation with ET-1 and negative correlation with NO, which suggesting that UⅡtakes some part in damaging the function of vascular endothelial . (3) The level of plasma UⅡmay become an effective indicator to vascular endothelial damages.
|
PDF Full Text Request